Company Overview of Ceragenix Pharmaceuticals, Inc.
Ceragenix Pharmaceuticals, Inc. operates as a medical device company focusing on dermatology and infectious diseases in the United States. The company has two base technology platforms, which include Barrier Repair for the treatment of dermatological disorders; and Ceragenins for the treatment of infectious disease. Its Barrier Repair technology is the platform for the development of two prescription topical creams, including EpiCeram, a prescription product for the treatment of dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including eczema, irritant contact dermatitis, and radiation dermatitis; and NeoCeram, a pediatric ba...
1444 Wazee Street
Denver, CO 80202
Founded in 2002
Key Executives for Ceragenix Pharmaceuticals, Inc.
Ceragenix Pharmaceuticals, Inc. does not have any Key Executives recorded.
Ceragenix Pharmaceuticals, Inc. Key Developments
SEC Orders Hearing On Registration Suspension Or Revocation Against Ceragenix Pharmaceuticals
Sep 19 13
In conjunction with trading suspension, the Securities and Exchange Commission (SEC) also instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Ceragenix Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries